Pancreatic cancer is a highly malignant digestive system tumor with a poor prognosis. Most
pancreatic cancer patients are diagnosed at an advanced stage or even metastasis due to …

This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma
risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further …

PURPOSE To report pancreas surveillance outcomes of high-risk individuals within the
multicenter Cancer of Pancreas Screening-5 (CAPS5) study and to update outcomes of …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Background and aim The International Cancer of the Pancreas Screening Consortium met in
2018 to update its consensus recommendations for the management of individuals with …

Background & Aims Screening of individuals who have a high risk of pancreatic ductal
adenocarcinoma (PDAC), because of genetic factors, frequently leads to identification of …

Purpose Deleterious germline mutations contribute to pancreatic cancer susceptibility and
are well documented in families in which multiple members have had pancreatic cancer …

Objective DNA-based testing of pancreatic cyst fluid (PCF) is a useful adjunct to the
evaluation of pancreatic cysts (PCs). Mutations in KRAS/GNAS are highly specific for …

Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that
include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic …

Despite considerable research efforts, pancreatic cancer is associated with a dire prognosis
and a 5-year survival rate of only 10%. Early symptoms of the disease are mostly …